<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461799</url>
  </required_header>
  <id_info>
    <org_study_id>CN-01</org_study_id>
    <nct_id>NCT00461799</nct_id>
  </id_info>
  <brief_title>Orlistat Treatment of Crigler-Najjar Disease</brief_title>
  <official_title>Orlistat Treatment of Unconjugated Hyperbilirubinemia in Crigler-Najjar Disease; A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>De Najjar Stichting</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine whether orlistat is effective in decreasing plasma
      unconjugated bilirubin levels in patients with Crigler-Najjar disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unconjugated hyperbilirubinemia in Crigler-Najjar (CN) disease is conventionally treated with
      phototherapy and/or phenobarbital. Life-long daily phototherapy has considerable
      disadvantages. Main problems are a decreasing efficacy with age and a profound impact of the
      intensive phototherapy regimen on the quality of (social) life. An alternative treatment
      option for unconjugated hyperbilirubinemia is based on intestinal capture of UCB by oral
      treatment. Particularly when plasma UCB concentrations are high as in CN disease, UCB can
      diffuse from the blood into the intestinal lumen across the mucosa. Intestinal capture of UCB
      followed by fecal excretion reduces the enterohepatic circulation of UCB and subsequently
      decreases plasma UCB concentration. We demonstrated in Gunn rats, the animal model for CN
      disease, that orlistat treatment decreases plasma UCB concentrations parallel with increased
      fecal fat excretion, and induces net transmucosal excretion of UCB from the blood into the
      intestinal lumen. In human adults, orlistat has been widely applied for treatment of obesity,
      without serious side effects. Recent studies in obese adolescents and prepubertal children
      indicate that short-term orlistat treatment is well-tolerated by children and generally has
      only mild side effects. In the present randomized, placebo-controlled trial we determined in
      patients with CN disease the effects of orlistat treatment on plasma UCB concentrations, and
      on fecal excretion of fat and UCB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease in plasma unconjugated bilirubin level during orlistat</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>increase in fecal fat excretion during orlistat</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>increase in fecal bilirubin concentration during orlistat</measure>
  </primary_outcome>
  <enrollment>16</enrollment>
  <condition>Crigler-Najjar Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>orlistat</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with Crigler-Najjar disease above the age of 7 years

        Exclusion Criteria:

          -  cholestasis, chronic malabsorption syndrome, pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anja M. Hafkamp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen and Erasmus University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maarten Sinaasappel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henkjan J. Verkade, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Hafkamp AM, Havinga R, Sinaasappel M, Verkade HJ. Effective oral treatment of unconjugated hyperbilirubinemia in Gunn rats. Hepatology. 2005 Mar;41(3):526-34.</citation>
    <PMID>15726662</PMID>
  </reference>
  <reference>
    <citation>Hafkamp AM, Havinga R, Ostrow JD, Tiribelli C, Pascolo L, Sinaasappel M, Verkade HJ. Novel kinetic insights into treatment of unconjugated hyperbilirubinemia: phototherapy and orlistat treatment in Gunn rats. Pediatr Res. 2006 Apr;59(4 Pt 1):506-12. Erratum in: Pediatr Res. 2007 Oct;62(4):488.</citation>
    <PMID>16549520</PMID>
  </reference>
  <reference>
    <citation>Nishioka T, Hafkamp AM, Havinga R, vn Lierop PP, Velvis H, Verkade HJ. Orlistat treatment increases fecal bilirubin excretion and decreases plasma bilirubin concentrations in hyperbilirubinemic Gunn rats. J Pediatr. 2003 Sep;143(3):327-34.</citation>
    <PMID>14517515</PMID>
  </reference>
  <reference>
    <citation>Verkade HJ. A novel hypothesis on the pathophysiology of neonatal jaundice. J Pediatr. 2002 Oct;141(4):594-5.</citation>
    <PMID>12378205</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2007</study_first_submitted>
  <study_first_submitted_qc>April 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <last_update_submitted>April 16, 2007</last_update_submitted>
  <last_update_submitted_qc>April 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2007</last_update_posted>
  <keyword>Crigler-Najjar disease.</keyword>
  <keyword>Bilirubin.</keyword>
  <keyword>Phototherapy.</keyword>
  <keyword>Orlistat.</keyword>
  <keyword>Unconjugated hyperbilirubinemia.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia</mesh_term>
    <mesh_term>Crigler-Najjar Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

